Next generation of ALK TKI inhibitors for treatment of advanced ALK-positive NSCLC

Alice Shaw reports on two studies' results presented on 2nd and 3rd generation ALK inhibitors in front- and further lines of treatment for ALK positive non-small cell lung cancer patients.

Abstracts as referenced in the ASCO 2017 programme:
LBA9008: Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.
9006: Efficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) with one or more prior ALK tyrosine kinase inhibitor (TKI): A phase I/II study.

Produced by the European Society for Medical Oncology
http://www.esmo.oncologypro.org

Видео Next generation of ALK TKI inhibitors for treatment of advanced ALK-positive NSCLC канала European Society for Medical Oncology